Nanoporous silica microparticle interaction with toll-like receptor agonists in macrophages

被引:22
|
作者
Cejudo-Guillen, M. [1 ,2 ]
Ramiro-Gutierrez, M. L. [3 ]
Labrador-Garrido, A. [1 ,2 ]
Diaz-Cuenca, A. [3 ]
Pozo, D. [1 ,2 ,4 ]
机构
[1] CABIMER Andalusian Ctr Mol Biol & Regenerat Med C, E-41092 Seville, Spain
[2] Univ Seville Med Sch, Dept Med Biochem Mol Biol & Immunol, E-41009 Seville, Spain
[3] CSIC Univ Seville, Mat Sci Inst Seville ICMS, E-41092 Seville, Spain
[4] BIONAND Andalusian Ctr Nanomed & Biotechnol, E-29590 Malaga, Spain
关键词
Nanoporous silica microparticles; Macrophage; Innate immunity; Toll-like receptor; MESOPOROUS SILICA; DRUG-DELIVERY; INNATE IMMUNITY; IN-VITRO; NANOPARTICLES; CELLS; BIOCOMPATIBILITY; PARTICLES; FUNCTIONALIZATION; CYTOTOXICITY;
D O I
10.1016/j.actbio.2012.07.026
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Nanoporous silica microparticles (NSiO2-MP) are considered to be potential drug delivery systems and scaffolding platforms in tissue engineering. However, few biocompatibility studies regarding NSiO2-MP interaction with the immune system have been reported. Toll-like receptors (TLR) are involved in host defence as well as autoimmune and inflammatory diseases. The results show that NSiO2-MP up to 100 mu g ml(-1) do not affect macrophage cell viability after 24 h cell culture. Moreover, NSiO2-MP do not compromise the cell viability of TLR-activated Raw 264.7 cells, for either cell surface TLR (TLR1/TLR2/TLR4/TLR6) or endocytic compartment TLR (TLR3/TLR7/TLR9). Furthermore, Raw 264.7 cells do not respond to NSiO2-MP exposure in terms of IL-6 or IL-10 secretion. NSiO2-MP co-treatment in the presence of TLR ligands does not impair or enhance the secretion of the pro-inflammatory cytokine IL-6 or the regulatory cytokine IL-10. Thus, NSiO2-MP do not affect macrophage polarization towards a pro-inflammatory or immunosuppressive status, representing added value in terms of biocompatibility compared with other SiO2-based micro- and nanoparticles. (C) 2012 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:4295 / 4303
页数:9
相关论文
共 50 条
  • [41] Facile syntheses of functionalized toll-like receptor 7 agonists
    Akinbobuyi, Babatope
    Byrd, Matthew R.
    Chang, Charles A.
    Nguyen, Mysa
    Seifert, Zacharie J.
    Flamar, Anne-Laure
    Zurawski, Gerard
    Upchurch, Katherine C.
    Oh, SangKon
    Dempsey, Stephen H.
    Enke, Thomas J.
    Le, John
    Winstead, Hunter J.
    Boquin, Jose R.
    Kane, Robert R.
    TETRAHEDRON LETTERS, 2015, 56 (02) : 458 - 460
  • [42] Toll-like receptor agonists: New opportunities for drug development
    Wagner, Hermann
    ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH, 2007, 57 (01): : 58 - 58
  • [43] Clinical setbacks for toll-like receptor 9 agonists in cancer
    Schmidt, Charlie
    NATURE BIOTECHNOLOGY, 2007, 25 (08) : 825 - 826
  • [44] Trial Watch Toll-like receptor agonists for cancer therapy
    Vacchelli, Erika
    Eggermont, Alexander
    Sautes-Fridman, Catherine
    Galon, Jerome
    Zitvogel, Laurence
    Kroemer, Guido
    Galluzzi, Lorenzo
    ONCOIMMUNOLOGY, 2013, 2 (08):
  • [45] Aerosolized Toll-like Receptor Agonists Suppress Allergic Inflammation
    Goldblatt, David
    Fouts, Adrienne
    Wali, Shradha M.
    Valverde-Ha, Gabriella
    Moczygemba-Martinez, Margarita
    Huston, David P.
    Tuvim, Michael J.
    Dickey, Burton
    Evans, Scott
    JOURNAL OF IMMUNOLOGY, 2020, 204 (01):
  • [46] Signaling by Toll-like receptor 2 and 4 agonists results in differential gene expression in murine macrophages
    Hirschfeld, M
    Weis, JJ
    Toshchakov, V
    Salkowski, CA
    Cody, MJ
    Ward, DC
    Qureshi, N
    Michalek, SM
    Vogel, SN
    INFECTION AND IMMUNITY, 2001, 69 (03) : 1477 - 1482
  • [47] Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia
    D E Spaner
    A Masellis
    Leukemia, 2007, 21 : 53 - 60
  • [48] Topical immunomodulation in dermatology: Potential of Toll-like receptor agonists
    Hengge, UR
    Ruzicka, T
    DERMATOLOGIC SURGERY, 2004, 30 (08) : 1101 - 1112
  • [49] Aerosolized Toll-Like Receptor Agonists Suppress Allergic Inflammation
    Goldblatt, D. L.
    Ha, G. Valverde
    Fouts, A.
    Wali, S.
    Martinez-Moczygemba, M.
    Huston, D. P.
    Tuvim, M. J.
    Dickey, B. F.
    Evans, S. E.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [50] Clinical setbacks for toll-like receptor 9 agonists in cancer
    Charlie Schmidt
    Nature Biotechnology, 2007, 25 : 825 - 826